Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581854 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00581854 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 22 participants.
The verdict
NCT00581854, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
Interventions
- DRUG modified Hyper-CVAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2000-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00581854
The ClinicalTrials.gov registry entry for NCT00581854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which modified Hyper-CVAD is the first listed.
NCT00581854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00581854 about?
NCT00581854 is a clinical study titled "Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma". rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
What is the current status of trial NCT00581854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2000-06. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00581854?
The interventions under investigation include: modified Hyper-CVAD (DRUG).
Who is sponsoring clinical trial NCT00581854?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.